Fueled by $111 Million, Sionna Therapeutics Takes Aim at Cystic Fibrosis

[cafead]

via Newly-launched Sionna Therapeutics is stepping up to the plate and challenging Vertex Pharmaceuticals in the cystic fibrosis space. Backed by OrbiMed, Sionna hit the ground with a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in CF patients.

article source